Downregulation of snoRNA SNORA52 and Its Clinical Significance in Hepatocellular Carcinoma

Table 3

Univariate and multivariate analysis of overall survival in HCC patients.

Clinicopathologic parameters	Univariate analysis		Multivariate analysis
	HR (95% CI)		HR (95% CI)
Age (<60 vs. ≥60)	1.153 (0.572-2.322)	0.691
Gender (female vs. male)	0.896 (0.344-2.331)	0.822
Hepatitis B (negative vs. positive)	1.056 (0.406-2.746)	0.911
AFP (<400 vs. ≥400)	1.614 (0.805-3.235)	0.177
Cirrhosis (present vs. absent)	0.918 (0.453-1.861)	0.812
Microvascular invasion (present vs. absent)	1.255 (0.382-4.126)	0.708
Tumor differentiation (low vs. high/moderate)	0.724 (0.357-1.469)	0.371
Capsular invasion (present vs. absent)	2.143 (1.070-4.293)	0.032	1.132 (0.530-2.419)	0.748
TNM stage (I~II vs. III~IV)	2.712 (1.348-5.455)	0.005	0.803 (0.299-2.157)	0.663
Tumor diameter (<5 cm vs. ≥5 cm)	5.113 (1.553-16.834)	0.007	9.292 (2.457-35.137)	0.001
Multiple lesions (present vs. absent)	3.607 (1.725-7.542)	0.001	3.548 (1.654-7.612)	0.001
Vessel carcinoma embolus (present vs. absent)	2.052 (0.919-4.582)	0.079	4.519 (1.737-11.759)	0.002
SNORA52 expression (low vs. high)	0.274 (0.127-0.594)	0.001	0.359 (0.161-0.802)	0.012

AFP: α-fetoprotein; TNM: tumor-node-metastasis; was considered to be statistically significant.